iCo Therapeutics Inc (CVE:ICO) traded up 18.2% during mid-day trading on Thursday . The stock traded as high as C$0.07 and last traded at C$0.07. 139,500 shares changed hands during mid-day trading, a decline of 74% from the average session volume of 544,139 shares. The stock had previously closed at C$0.06.
TRADEMARK VIOLATION NOTICE: This story was originally posted by PressOracle and is the sole property of of PressOracle. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://pressoracle.com/news/2019/01/12/ico-therapeutics-ico-trading-18-2-higher.html.
iCo Therapeutics Company Profile (CVE:ICO)
iCo Therapeutics Inc, a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections.
Featured Article: How to calculate the intrinsic value of a stock
Receive News & Ratings for iCo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iCo Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.